Following people with ANCA-associated vasculitis in Hunan, China
Follows people with ANCA-associated vasculitis over time, without giving any treatment.
Plain-language title generated from the registry record
Registry title: Multicenter Cohort Study of AAV in Hunan of China
Key facts
- Where
- Changsha, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for people with ANCA-associated vasculitis in Hunan province of China. Patients are followed for at least 5 years.
- Sex
- All sexes can join.
- Disease stage
- People who fulfill the 2012 criteria of ANCA-associated vasculitis.
Main reasons for not taking part
- People who do not agree to sign informed consent
Read by machine on 12 November 2026.
Where in China
- Xiangya HospitalChangsha, ChinaContact: Yong Zhong, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT05315141
- Record updated
- 7 April 2022
- Original description
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.Read full original descriptionShow less
Multicenter Cohort Study of ANCA-associated Small Vasculitis in Hunan Province of China
This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA）-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.
Inclusion: Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed consent.
Exclusion: Do not agree to sign informed consent.